window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : October 4, 2025

  • News
  • About Us
Contact Us

Central Nervous System

  • Central Nervous System,Chronic diseases,Drug Delivery & Formulation,European biotech,Pharmaceuticals and therapeutics

    Neuraxpharm launches next-generation oral fumarate Riulvy for multiple sclerosis in Germany

    Neuraxpharm Group has launched Riulvy (tegomil fumarate) in Germany, marking [...]

    October 3, 2025
  • Biologics & Biosimilars,Central Nervous System,Chronic diseases,Clinical Development,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics,Research & Development

    Levicept to present Phase 2 LEVI-04 data showing bone marrow lesion and pain reduction at ACR Convergence 2025

    Levicept Ltd will present new findings from its Phase 2 [...]

    October 2, 2025
  • Cell & Gene Therapy,Central Nervous System,Clinical Trials,Neurosciences,Pharmaceuticals and therapeutics,Research & Development

    Gene therapy AMT-130 slows Huntington’s disease progression in early trial

    A gene therapy developed by uniQure appears to slow progression [...]

    September 25, 2025
  • Central Nervous System,Clinical Development,Market Access & Commercialization,Patient Centricity,Pharmaceuticals and therapeutics

    Bristol Myers Squibb to launch Cobenfy in the UK at US list price for adults with schizophrenia

    Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium [...]

    September 23, 2025
  • Central Nervous System,Clinical Development,Clinical Trials,Neurosciences,Partnerships & Funding,Rare Diseases

    Servier acquires Kaerus drug candidate for Fragile X syndrome, the most common genetic cause of autism

    Servier has acquired KER-0193 from Kaerus Bioscience, gaining a potential [...]

    September 16, 2025
  • Central Nervous System,Clinical Trials,Data Management,Research & Development

    New study shows covariate adjustment improves trial precision for pain, mood and fatigue outcomes

    A study published in the Journal of Pain has shown [...]

    September 16, 2025
  • Cell & Gene Therapy,Central Nervous System,Research & Development

    $2.5M awarded to fuel breakthrough research into tau-driven neurodegenerative diseases

    The Rainwater Charitable Foundation, Aging Mind Foundation, Alzheimer’s Association, and [...]

    August 15, 2025
  • Central Nervous System,Chronic diseases,Clinical Trials,Drug Development,Pharmaceuticals and therapeutics,Research & Development

    Preclinical study shows evenamide targets schizophrenia pathology in the hippocampus

    Newron Pharmaceuticals has highlighted new preclinical findings published in Neuropsychopharmacology [...]

    August 11, 2025
  • Central Nervous System,Clinical Trials,Digital Health,Pharmaceuticals and therapeutics

    Investigational schizophrenia digital therapeutic meets key goal in late-stage study

    An investigational prescription digital therapeutic (PDT) designed to treat negative [...]

    August 14, 2025
  • Central Nervous System,Clinical Trials,Drug Development,Precision medicine

    HMNC Brain Health reports precision-guided success in Phase 2 depression trial

    A genetically targeted approach to depression treatment has shown promising [...]

    August 6, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • HeliosX strengthens leadership team to drive global growth and brand innovation
    Categories: Digital Health, Global health, Market Access & Commercialization, Movers & Shakers, Patient Centricity, Pharmaceuticals and therapeutics, Technology and platforms
  • SeaBeLife secures €2 million to advance dual-targeted therapies for dry AMD and severe acute hepatitis
    Categories: Biotech, Clinical Development, Clinical Trials, Drug Development, Global health, Partnerships & Funding, Rare Diseases, Research & Development
  • Amorphical reports positive interim results from ongoing Crohn’s disease trial
    Categories: Chronic diseases, Clinical Development, Clinical studies, Clinical Trials, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top